DBV sinks following peanut allergy trial miss, Aimmune soars

Shares of DBV Technologies (DBVT) are sinking after the company announced that its Phase III study in peanut allergic patients ages four to 11 years missed the primary endpoint. The stock is down 46%, or $22.35, to $25.72 in after-hours trading. DBV said it will continue ongoing discussions with the FDA and plans to proceed with the Biologics License Application preparation process. Shares of Aimmune Therapeutics (AIMT), a company also in Phase III with a peanut allergy treatment, are soaring. The stock is up 56%, or $14.24, to $39.90.